Project description:Purified human ITPRIPL1-extracellular domain (ITPRIPL1-ECD) protein or PBS was added to human peripheral blood mononuclear cells (PBMCs) as a widely used source of immune cells and treated for 18 hours under 37℃, 5% CO2 in separate 1.5 ml EP tubes (n=3 independent samples for each condition)
Project description:This SuperSeries is composed of the following subset Series: GSE16945: Comparative transcription profiling of peripheral blood mononuclear cells from vasculitis patients GSE18247: Focused transcription profiling of peripheral blood mononuclear cells from vasculitis patients Refer to individual Series
Project description:This SuperSeries is composed of the following subset Series:; GSE15389: Peripheral blood mononuclear cells treated with a CDK inhibitor; GSE15392: DU145 tumor cells treated with a CDK inhibitor; GSE15395: HCT116 tumor cells treated with a CDK inhibitor Experiment Overall Design: Refer to individual Series
Project description:Zoledronate is well known to act on osteoclasts to inhibit bone resorption.Zoledronate is administrated intravenously in clinical use, however, actions of zoledronate on cells in blood circulation are not fully understood. To understand its actions of human peripheral blood mononuclear cells (h-PBMC), we performed gene expression profiling in zoledronate-treated h-PBMC.
Project description:We report RNA-sequencing analysis of human peripheral blood mononuclear cells exposed to clinically recommended doses (500 nM) of the HSP90 inhibitor ganetispib. Global analysis of the expression profiles of treated cells revealed wide spread changes in gene expression, specifically, upregulation of protein folding and assembly pathways, with downregulation of antigen presentation through MHC Class I and Class I.